Advancing precision oncology requires effective biomarker testing and actionable insights that drive better patient outcomes. With next-generation sequencing (NGS) testing in your hospital, you can get the insights you need when you need them — in days, not weeks.
Multigene NGS assays mean more patients can be successfully tested without the need for rebiopsies. But not all NGS is the same.
Targeted panels give you actionable insights for the biomarkers that enable you to match patients to approved treatments or clinical trials.
Targeted panels are a great option, especially compared to expensive outsourced tests that often provide thousands of meaningless data points.
With your sample and testing expertise onsite, your multidisciplinary team is always empowered with the information they need to tailor patient treatments for better outcomes.
Did you know that traditional, sequential single-gene testing can cost as much or more than a NGS multigene assay? In-house NGS can help you save time and money.
Clinical guidelines strongly recommend NGS panel testing to quickly assess patients and develop care plans.
Outsourcing was a logical choice in the early days of biomarker testing when there were only a few known biomarkers.
Today, as the number of new biomarkers continues to escalate, along with the development of associated therapies, the need for NGS testing continues to intensify.
Fortunately, technology has advanced in parallel so that hospitals can easily bring highly automated NGS in-house to benefit patients, maximize efficiency and minimize costs.
Find more information on the benefits of next-generation sequencing and how it can benefit your institution and patients
Get insights on biomarker testing - present and future. Read the article in European Medical Group now.